Stock Events

Genprex 

$2.02
36
+$0+0% Thursday 13:35

Statistics

Day High
2.02
Day Low
2.02
52W High
7.99
52W Low
0.19
Volume
174
Avg. Volume
2,261
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

22MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-3.96
-2.64
-1.32
0
Expected EPS
-2.54
Actual EPS
-3.96

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0A8I.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Ayala Pharmaceuticals
ADXS
Mkt Cap10.35M
Advaxis, Inc. is involved in the discovery, development, and commercialization of cancer immunotherapies, offering a direct alternative to Genprex's oncology treatments.
Gilead Sciences
GILD
Mkt Cap87.16B
Gilead Sciences, Inc. has a broad portfolio of cancer therapies, including gene therapies, making it a major competitor in the oncology market.
Bluebird bio
BLUE
Mkt Cap133.39M
bluebird bio, Inc. specializes in gene therapies for genetic diseases and cancer, directly competing with Genprex's gene therapy approach.
Sangamo Therapeutics
SGMO
Mkt Cap94.38M
Sangamo Therapeutics, Inc. focuses on genomic medicine, including gene therapy, gene editing, and gene regulation, competing in the same innovative treatment space as Genprex.
CRISPR Therapeutics
CRSP
Mkt Cap4.92B
CRISPR Therapeutics AG is a leader in gene editing technology, which can be applied to cancer treatment, making it a competitor in the gene therapy market.
Intellia Therapeutics
NTLA
Mkt Cap2.49B
Intellia Therapeutics, Inc. is involved in CRISPR/Cas9 gene editing, a cutting-edge technology for treating genetic diseases and cancer, competing with Genprex's gene therapy approach.
Editas Medicine
EDIT
Mkt Cap455.6M
Editas Medicine, Inc. works on gene editing technologies, including CRISPR, for the treatment of serious diseases, offering an alternative to Genprex's therapies.
Alnylam Pharmaceuticals
ALNY
Mkt Cap32.95B
Alnylam Pharmaceuticals, Inc. focuses on RNAi (RNA interference) therapeutics for the treatment of genetic diseases, indirectly competing with Genprex's gene therapy approach by offering a different method of genetic intervention.

About

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Show more...
CEO
Mr. John Rodney Varner
Employees
22
Country
United States
ISIN
US3724462037
WKN
000A2JHMQ

Listings